Search PubMed⌕ Search

Biomedical subjects

A Stacher

Publications and source records attributed to A Stacher.

At least 37 records · Page 2Linked to original sources
PubMed1979

[A clinical study of the non-Hodgkin's lymphomas according to the Kiel classification (author's transl)].

A study of 138 patients with Non-Hodgkin's lymphomas was performed. The results were compared with retro- and prospective investigations of patients of the Kiel lymphoma study group. The aim of the study is to evaluate the value of the Kiel classification for the therapy and prognosis of malignant lymphomas. The malignant lymphomas of low- and high-grade malignancy differ significantly in their biological behaviour. Especially the clinical progress of the disease and the response to therapy are different. The lymphomas of low-grade malignancy may not need any treatment for long periods in some patients. In contrary, patients with lymphomas of high-grade malignancy need an active treatment immediately after the establishment of the diagnosis. In stages I and II radiotherapy is sufficient, in stages III and IV chemotherapeutic regimens are necessary. Each type of malignant lymphoma may be accompanied by leukemia. Most of the malignant lymphomas, particularly the immunocytomas, may produce monoclonal gammopathies, most of them being macroglobulinemias. Thus the macroglobulinemia Waldenström is just a clinical necessary to evaluate the significance of the subtypes of the Kiel classification for the planning of specific treatment.

Adolescent↗
PubMed1979

[Anemias resulting from iron metabolism disorders].

For the most part iron deficiency, but also disturbances of distribution, transport and utilization of iron, are able to cause anemias. To understand the origin of such anemias, firstly iron metabolism, then the clinical symptomatology as well as the laboratory parameters necessary for diagnosis and finally the usual therapies are described.

Anemia, Hypochromic↗
PubMed1977

Treatment of acute non-lymphoid leukemias: comparison of two protocols.

The results of treatment of 57 patients suffering from acute non-lymphoid leukemia by two protocols are compared. The more aggressive Coap protocol rendered a higher remission rate (57.1%), than the mild Guyer protocol where the remission rate has been 25%. The best results have been achieved in the former group in the younger population; in the latter group there has been no age-effect relationship. Although the remission rate differed in both protocols there has been no statistically significant difference in survival.

Cyclophosphamide↗
PubMed1977

[Retrospective analysis of the clinical relevance of the Kiel classification of malignant non-Hodgkin's lymphomas (author's transl)].

405 cases with non-Hodgkin's lymphomas have been diagnosed according to the Kiel classification and analysed retrospectively. 314 patients with non-Hodgkin's lymphomas of low-grade-malignancy (chronic lymphocytic leukemia, lymphoplasmacytoid, centrocytic, centrocytic, centroblastic-centrocytic lymphoma) manifested significantly higher median survival times than the 91 patients with non-Hodgkin's lymphomas of high-grade malignancy (lymphoblastic and immunoblastic lymphoma). Within the group of patients with low-grade malignant lymphomas distinct prognostic differences were found whereas survival times in patients with lymphoblastic or immunoblastic lymphomas were rather similar. The lymphoblastic lymphoma showed a bimodal curve of age distribution whilst all other lymphomas had a maximum of incidence in the seventh decade of life. Increased frequency of B-symptoms did not necessarily represent an unfavorable prognostic factor for the lymphoma entity concerned. Except for chronic lymphocytic leukemia the highest incidence of initial bone marrow involvement was seen in lymphoplasmacytoid, centrocytic and lymphoblastic lymphomas. Centrocytes have been observed in peripheral blood of patients with centrocytic and centroblastic-centrocytic lymphomas, even though lymphocytosis did not exist. Monoclonal hypergammaglobulinemia was found in only 43% of the sera from patients with lymphoplasmocytoid lymphoma. In this disease, it was possible to differentiate between a lymphonodal, a splenomegalic and an extranodal manifestation.

Age Factors↗
PubMed1976

[New polymerase gene in pancytopenia (author's transl)].

Increasing evidence has accumulated that the direct assay of reverse transcriptase in human blood cells is of value in the diagnosis of leukaemia. The isolation and characterization of this enzyme has shown that it possesses remarkable similarities to the DNA-polymerase of the RNA-tumour virus of simian sarcoma. Hence, leukaemic cells in humans are thought to possess a virus-related gene, namely, reverse transcriptase. Various clinical reports have established the presence of this enzyme in blood cells, not only in the case of morphologically-proven malignant change, but also in cases classified as non-leukaemic from the morphological picture, such as acute leukaemia in remission and in the pre-leukaemic state. In confirmation and augmentation of earlier views we now report on the presence of reverse transcriptase in a patient with pancytopenia, who subsequently developed acute leukaemia i.e. isolation of the enzyme occurred in the pre-leukaemic state.

Clinical Enzyme Tests↗
PubMed1976

Production and diagnostic application of anti-human T-cell antisera.

This paper is intended to demonstrate the extension of experimental procedures used for the production of anti-chicken T-cell sera to the manufacturing of anti-human T-cell sera. Specific anti-chicken bursa (ABS) and anti-chicken thymus cell sera (ATS) were prepared in turkeys. The in vitro specificity of these sera was assessed by means of immunofluorescence and lymphocytotoxicity tests. The selective immunosuppressive effect of ABS was demonstrated in Obese strain (OS) chickens with spontaneous autoimmune thyroiditis, that of ATS in a skin allograft system. A specific anti-human T-cell serum was prepared by immunizing a horse with fetal human thymus cells. After appropriate exhaustive absorptions this serum was found to react specifically with human T-cells. An anti-T cell globulin (ATG) fraction prepared from the absorbed antiserum was then labelled with FITC for use in direct immunofluorescence tests. The potential diagnostic value of T-cell specific antibodies is discussed.

Animals↗
PubMed1975

Chemotherapy of malignant lymphomas.

In malignant lymphomas generally, radiotherapy is the treatment of choice. Chemotherapy cannot be very effective in lymphomas of the CNS because most of the cytostatic drugs in question are not able to pass the blood-brain barrier. But in cases in which malignant lymphomas are disseminated throughout the body including the CNS, cytostatic chemotherapy is the only means of prolonging the life of the patient. In such cases one has to distinguish between Hodgkin's disease and non-Hodgkin lymphomas. Alkylating agents, metaphase inhibitors and antibiotics are used in the treatment of malignant lymphomas. The best results are achieved with combination schedules. In Hodgkin lymphomas the so-called MOPP-schedule is the most effective. In non-Hodgkin lymphomas the same drugs are ususally given without procarbacine. After having achieved a remission, maintenance therapy is very important. Vinblastine and Chlorambuzil are able to prolonge the remission. When resistance to these drugs occurs Bleomycin, Adriamycin, CCNU and Peptichemio are effective agents. The results as well as the side effects of such regimens are described.

Antineoplastic Agents↗
PubMed1975

A case of acute lymphoblastic leukemia and thorotrast-accumulation.

A case of acute lymphoblastic leukemia (ALL), in a 50 years old patient, 26 years after thorotrast injection, is reported. In spite of intensive therapy, he died 2 years after diagnosis of disease. The cytogenetic showed the usual thorotrast radiation-induced abnormalities, although to a greater extent than reported in leterature. Furthermore a hypodiploidy was present, which was connected with ALL. In addition the patient exhibited the interesting phenomenon of giant satellites on one of his D14-chromosomes. This abnormally was found also in his mother and son. The question arises, how far the inherited cytogenetic pattern and the thorotrast radiation each contributed to the development of ALL.

Bone Marrow Examination↗
PubMed1975

[Adriamycin effects of PHA-stimulated lymphocytes].

The effect of adriamycin on PHA-stimulated lymphocytes is dose-dependent. An adriamycin concentration of 0.2 mug/ml reduces blast transformation and RNA synthesis as well as cell proliferation (DNA-synthesis). The lower concnetration of 0,01 mug/ml, which can be found inpatients for several hours after i.v. application, results only in a transitional inhibition of uridine nucleolar labelling. This inhibition of uridine nucleolar labelling appears more rapidly after adriamycin addition than that of thymidine labelling. Lymphocytes preincubated with adriamycin are effected similarly to lymphocyte cultured in the continuous presence of adriamycin.

Cell Division↗
PubMed1975

In-vitro inhibition of RNA-instructed DNA polymerase.

Rifamycins and distamycins were assayed in vitro for their effects on the activity of a reverse transcriptase derived from the plasma of a patient with breast cancer. The inhibitory effect observed was compared with that of a human placental substance with a molecular weight of approximately 10 000. The latter substance is apparently also capable of affecting reverse transcriptase activity in vitro.

Breast Neoplasms↗